Nevertheless, a phase I/II trial study using Navitoclax in combination with dabrafenib (BRAF inhibitor) and trametinib (MEK inhibitor) is recruiting unresectable or metastatic patients with BRAF mutant melanoma (ClinicalTrials.gov, NCT01989585). Here, BRAF is linked to melanoma.